{
    "clinical_study": {
        "@rank": "84077", 
        "arm_group": [
            {
                "arm_group_label": "carbetocin", 
                "arm_group_type": "Active Comparator", 
                "description": "single 100 \u03bcg IV dose of carbetocin (150 women)  after fetal extraction and before placental removal."
            }, 
            {
                "arm_group_label": "Syntometrine", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal."
            }
        ], 
        "brief_summary": {
            "textblock": "to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of\n      Postpartum hemorrhage after cesarean section"
        }, 
        "brief_title": "Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Postpartum Hemorrhage", 
            "Blood Loss"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "A double blind randomized study conducted on 450 pregnant subjected randomly either to\n      single 100 \u03bcg IV dose of carbetocin (150 women) or combination of 5 IU oxytocin and 0.2 mg\n      ergometrine (300 women) after fetal extraction and before placental removal.\n\n      Prevention of postpartum haemorrhage (PPH) after cesarean section (CS) had been evaluated by\n      measurement of drop of Hemoglobin and hematocrit, incidence of PPH and number of subjects\n      needed additional oxytocic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All participants are at 37 - 40 weeks of gestational age\n\n          -  Noncomplicated pregnancy.\n\n        Exclusion Criteria:\n\n          -  Participants with placenta previa\n\n          -  Patients with coagulopathy\n\n          -  preeclamptic women\n\n          -  known sensitivity to oxytocin or methergine were excluded"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "39 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044549", 
            "org_study_id": "Carbitocin"
        }, 
        "intervention": [
            {
                "arm_group_label": "carbetocin", 
                "description": "Oxycontin analogue", 
                "intervention_name": "carbetocin", 
                "intervention_type": "Drug", 
                "other_name": "Pabal"
            }, 
            {
                "arm_group_label": "Syntometrine", 
                "description": "Uterotonins", 
                "intervention_name": "Syntometrine", 
                "intervention_type": "Drug", 
                "other_name": "Oxytocin methergine combination"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxytocin", 
                "Carbetocin", 
                "Syntometrine", 
                "Ergonovine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Carbetocin", 
            "syntometrine", 
            "postpartum hemorrhage", 
            "cesarean section"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt", 
                    "zip": "12151"
                }, 
                "name": "Ahmed Maged"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section", 
        "overall_official": {
            "affiliation": "Ass prof kasr aini medical school", 
            "last_name": "Ahmed Maged, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of participants experienced postpartum hemorrhage", 
            "measure": "prevention of post partum hemorrhage after CS", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044549"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cairo University", 
            "investigator_full_name": "Ahmed Maged", 
            "investigator_title": "Assistant professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Number of subjects experienced Hemodynamic changes (blood pressure , pulse and respiratory rate ) , GIT side effects as nausea , vomiting and metallic taste, Vasomotor effects as flushing, headache , itching", 
            "measure": "side effects of drugs used", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "source": "Cairo University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cairo University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}